Key Updates in Metastatic HER2+ Breast Cancer

Opinion
Video

Sara M. Tolaney, MD, MPH, reviews key clinical trial data recently updated in the metastatic HER2+ breast cancer treatment space.

This is a synopsis of an OncView series featuring Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institute.

Sara M. Tolaney, MD, MPH, Chief of Breast Oncology at Dana-Farber Cancer Institute, discussed major advances in metastatic HER2-positive breast cancer, including the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) and the HER2-specific tyrosine kinase inhibitor (TKI) tucatinib.

The DESTINY-Breast03 trial showed T-DXd tripled progression-free survival (PFS) and improved overall survival compared to trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer. With a 28-month PFS, T-DXd exceeded the 18-month PFS seen with first-line standard-of-care trastuzumab, pertuzumab, and a taxane (THP). Ongoing trials are testing T-DXd in earlier lines, including first-line in DESTINY-Breast09. If positive, T-DXd may replace THP upfront.

The HER2CLIMB trial added tucatinib to capecitabine and trastuzumab, showing improvements in PFS and overall survival over capecitabine/trastuzumab alone, including in the 50% of patients with treated or active brain metastases. This is the first HER2-targeted therapy to show survival benefit in brain metastases. Tucatinib’s label allows second-line use, sparing some patients upfront brain radiation.

While studies suggest T-DXd has intracranial activity, direct comparisons are lacking as most T-DXd trials excluded active brain metastases. Additional results are expected from trials like DESTINY-Breast12 specifically evaluating T-DXd in this population.

Both tucatinib- and T-DXd-containing regimens have shown substantial efficacy in advanced HER2-positive disease, though optimal sequences are still being defined. Ongoing trials continue to evaluate combinations and positioning to maximize the impact of these promising new targeted therapies.

In summary, T-DXd and tucatinib represent major recent advances providing more effective and brain-penetrant options for patients with previously poor prognosis metastatic HER2-positive breast cancer.

*Video synopsis is AI-generated and reviewed by Cancer Network editorial staff.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
Related Content